期刊
CANCER IMMUNOLOGY RESEARCH
卷 3, 期 8, 页码 836-843出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-15-0112
关键词
-
资金
- NIH [CA174795, CA172164]
- V Foundation
- Bridge Project of the Koch Institute
- Dana-Farber/Harvard Cancer Center
- Hertz Foundation
- NSF
- NATIONAL CANCER INSTITUTE [R01CA172164, R01CA174795] Funding Source: NIH RePORTER
Recently, a number of promising approaches have been developed using synthetic chemistry, materials science, and bioengineering-based strategies to address challenges in the design of more effective cancer vaccines. At the stage of initial priming, potency can be improved by maximizing vaccine delivery to lymph nodes. Because lymphatic uptake from peripheral tissues is strongly size dependent, antigens and adjuvants packaged into optimally sized nanoparticles access the lymph node with much greater efficiency than unformulated vaccines. Once primed, T cells must home to the tumor site. Because T cells acquire the necessary surface receptors in the local lymph node draining the tissue of interest, vaccines must be engineered that reach organs, such as the lung and gut, which are common sites of tumor lesions but inaccessible by been designed that entrap or slowly release immunomodulators at the tumor site, reducing systemic exposure and improving therapeutic efficacy. Finally, lessons learned from the design of biomaterial- based scaffolds in regenerative medicine have led to the development of implantable vaccines that recruit and activate antigen-presenting cells to drive antitumor immunity. Overall, these engineering strategies represent an expanding toolkit to create safe and effective cancer vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据